Tianwu Tech Secures Over RMB 100 Million Series A Funding to Advance AI-Driven Protein Design and Bio-Manufacturing Innovation

VCBeat learned第一时间 that on November 15, Matwings Technology, an internationally leading AI protein design company, announced the completion of an over RMB 100 million Series A round of financing. This round of financing was led by Qiming Venture Partners, with participation from YONGHUA, Jingtao Capital, and existing shareholder 3E Bioventures. The funds raised will be mainly used for the development of in-house projects and the continuous iteration and upgrading of AccelProtein™, a general artificial intelligence for protein design (originating from the Pro series artificial intelligence developed by the Hong Liang team at Shanghai Jiao Tong University), to ensure that Matwings Technology maintains a leading position in global technological innovation and market competitiveness.

Proteins are omnipresent in our daily lives and production, serving as the foundation for sustaining life activities and driving technological innovation. High-performance protein products are the source of progress in many industries, including biomedicine, green energy, food health, and green chemical engineering. However, traditional methods of obtaining high-performance proteins often face challenges such as high costs, complex processes, and low success rates.

The innovation of Matwings Technology lies in its self-developed general artificial intelligence for protein design, AccelProtein™, which is capable ofDirectly predicting protein function breaks through the limitations of structure prediction methods represented by AlphaFold, which "can only predict structure but cannot design function," providing a completely new technical means for obtaining proteins with excellent functions, and standing out uniquely in the industry.

Currently, Matwings Technology's general artificial intelligence for protein design, AccelProtein™, has achieved directed mining and evolution of proteins in numerous scenarios within the biopharmaceutical and synthetic biology fields, including significant improvements in metrics such as protein thermal stability, activity, affinity, extreme pH tolerance, immunogenicity, and yield.

In the CMC stage of biopharmaceuticals, AccelProtein™ can enhance the activity, specificity, thermal stability, and pH stability of key tool enzymes and tool proteins; in the early large-molecule screening stage, it improves the affinity and functional activity of fusion proteins, antibodies, cytokines, and others towards their targets; in the candidate molecule optimization stage, it provides druggability index modification and property optimization (including enhancing molecular stability, reducing viscosity, etc.), precisely addressing the critical pain points pharmaceutical companies face during R&D and production.

In the field of synthetic biology, Matwings Technology relies on AccelProtein™ for enzyme modification, enzyme mining, and enzyme catalysis process development, addressing the precise synthesis challenges of high-value molecules that are difficult to solve through chemical synthesis or natural extraction. It provides efficient and green AI enzyme catalysis solutions for fields such as pharmaceutical intermediates, fragrances, health product ingredients, and cosmetic raw materials.

After more than three years of accumulation, Matwings Technology has successfully delivered over 30 protein design projects, serving leading enterprises in various industries such as innovative drugs, in vitro diagnostics, pharmaceutical intermediates, nutritional health products, food and beverages, cleaning and textiles, and bio-agriculture. In the future, Matwings Technology will further deepen the application of its AI protein design technology, accelerate innovation in the biopharmaceutical and synthetic biology fields, and promote bio-manufacturing towards a more efficient and environmentally friendly direction.